Navigation Links
Cerimon to Conduct a Proof of Concept Study for Basiliximab for Noninfectious Uveitis, a Potentially Sight-Threatening Inflammation of the Eye
Date:3/10/2008

SOUTH SAN FRANCISCO, Calif., March 10 /PRNewswire/ -- Cerimon Pharmaceuticals announced today it has entered into an agreement with Novartis Pharma AG to conduct a proof of concept study for Simulect(R) (basiliximab) for the treatment of noninfectious uveitis, an autoimmune inflammation of the eye's internal structures. Uveitis can cause severe visual impairment and accounts for an estimated 10 percent of blindness cases in the Western World. Basiliximab is a monoclonal antibody that selectively blocks the interleukin-2 (IL-2) receptor. This mechanism of action provides highly targeted inhibition of the T-lymphocyte activation that is involved in serious immune-related diseases.

"There is a significant need for new effective therapies for the treatment of noninfectious uveitis patients. Part of Cerimon's overall strategy is to expand our basiliximab development program into other autoimmune diseases where there is significant medical need," commented Paul Sekhri, President and CEO of Cerimon Pharmaceuticals. "The agreement also exemplifies our strong relationship with Novartis, one of the leading worldwide pharmaceutical companies."

Dr. Daniel Levitt, Cerimon's Executive Vice President of Research and Development, stated, "Based on the mechanism of action of basiliximab, we believe this compound is well-suited to the treatment of noninfectious uveitis, a chronic eye inflammation that can lead to complications such as glaucoma, cataract, and vision loss. Basiliximab has the potential to significantly improve the quality of life for this group of uveitis patients and reduce adverse events often associated with current treatments that include corticosteroids and other immunosuppressive therapies."

In February 2006, Cerimon licensed basiliximab from Novartis for the treatment of Inflammatory Bowel Disease (IBD). In April 2007, Cerimon initiated a Phase IIb clinical study, titled ARREST UC-1 (Achieve Remission & Reduce or Eliminate Steroid The
'/>"/>

SOURCE Cerimon Pharmaceuticals, Inc.
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2

Related medicine news :

1. SpineMark, NeuStrategy Partner to Conduct Nations First Spine COE Survey(TM)
2. Nursing Home Workers Strike Over Employer Misconduct
3. Parents Identify Health Topics They Want Doctors to Discuss with Kids - New Research for University of Michigan Conducted by Knowledge Networks
4. inVentiv Health to Announce Fourth Quarter and Full Year 2007 Results and Conduct Conference Call on Thursday, February 28th
5. The Willie Gary Law Firm Files $1 Billion Lawsuit Against Durham County LME, Wake County LME, Five County LME, Mecklenberg County LME and Value Options, Inc. for Negligent and Intentional Misconduct Against Mental Health Agency
6. Doctors Group Sues Texas Medical Board for Misconduct; Cites Institutional Culture of Retaliation & Intimidation
7. Heavy drinking, conduct disorder linked to high-risk sexual behavior
8. Micromet Receives Regulatory Approval to Conduct a Phase 2 Clinical Trial Investigating MT103 (MEDI-538) in Patients with Acute Lymphoblastic Leukemia
9. Novel semiconductor structure bends light wrong way -- the right direction for many applications
10. CareTech Solutions Executive to Conduct Presentation on Creating a Healthy Revenue Cycle at AHIMA Convention and Exhibit
11. inVentiv Health to Announce Third Quarter Results and Conduct Conference Call on Wednesday, November 7, 2007
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/13/2014)... By Serena Gordon ... -- A new type of sensor for people with ... body using saliva instead of blood, researchers report. Scientists ... successfully tested it using artificial saliva. It uses light, metal ... blood sugar. "Everybody knows that diabetics have to prick ...
(Date:7/13/2014)... July 13, 2014 Athletes with a ... period from concussions, according to research presented today at ... ) Annual Meeting. The research marks the first of ... on the known physical events that occur after a ... a long allele in the (GT)n genotype were four ...
(Date:7/13/2014)... 13, 2014 Recently, 2014QuinceaneraDresses.com, the ... unveiled its new range of gorgeous Quinceanera ... the demand for elegant Quinceanera outfits is huge. ... items. All the company’s newly released dresses are ... are all elegant and vivid. , It ...
(Date:7/13/2014)... Recently, MyDressCity.com, one of the most popular suppliers of ... its new range of elegant Quinceanera dresses . ... discounted prices. Worldwide clients can enjoy this special offer ... online shop, there are plenty of beautiful dresses for ... materials. MyDressCity.com’s hot items are prom gowns, bridesmaid gowns, ...
(Date:7/13/2014)... July 13, 2014 Epidemiologists forecast an ... the 6MM, from 8,062 diagnosed incident cases in 2013 ... Annual Growth Rate (AGR) of 4.35%, during the forecast ... number of diagnosed incident cases of aGVHD in the ... have the lowest number of diagnosed incident cases of ...
Breaking Medicine News(10 mins):Health News:Saliva Test Might Someday Replace Needle Prick for Diabetics 2Health News:Saliva Test Might Someday Replace Needle Prick for Diabetics 3Health News:Genetic Factors May Be Responsible for Slowing Concussion Recovery in Athletes 2Health News:2014QuinceaneraDresses.com Releases Its New Quinceanera Dresses 2Health News:Cheap Elegant Quinceanera Dresses Unveiled by MyDressCity.com 2Health News:Graft-Versus-Host Disease Market (GVHD) Growing at 4.35% AGR to 2023 Says a New Report Available at ReportsnReports.com 2Health News:Graft-Versus-Host Disease Market (GVHD) Growing at 4.35% AGR to 2023 Says a New Report Available at ReportsnReports.com 3Health News:Graft-Versus-Host Disease Market (GVHD) Growing at 4.35% AGR to 2023 Says a New Report Available at ReportsnReports.com 4
... research suggests that the patients who undergo surgery to ... later developing pancreatic cancer. The investigators base their findings ... operation known as gastrectomy to remove their ulcers.// ... the stomach or a portion of the small intestine, ...
... has sex and any subsequent risk of birth defects such ... of sex might increase the risk of birth defects in ... and gynecology at Baylor College of Medicine in Houston told ... known causes of birth defects in lower animals. ...
... The government approved a long-awaited treatment for lymphoma - ... radiation directly to cancer cells. Idec Pharmaceuticals' Zevalin becomes ... US. // ,It's a new approach, adding ... CD20 found on lymphoma cells. The antibodies attach to ...
... group have developed an efficient method of identifying strains ... diseases such as meningococcal disease. The Cooperative ... Technology (QUT) has taken advantage of two new technologies// ... recently - DNA chip technology and comparative gene sequence ...
... which could make gene therapy powerful. The advance which is ... the modified genes to slip right into the cell nucleus.A ... an entire human.// ,This means that the DNA molecule ... smuggle or slip their modified DNA strands into the cells ...
... to a new study, filtering out the antibodies that can ... live donor transplants. Many patients need a kidney transplant but ... Body organs, from dead bodies, are in short supply, and ... must be of a compatible blood group. ,But ...
Cached Medicine News:Health News:Ulcer Surgery connected to danger of Pancreatic Cancer 2Health News:Identifying bacteria made amiable 2
(Date:7/11/2014)... -- Rock Creek Pharmaceuticals, Inc. (NASDAQ: RCPI ), ... and Drug Administration ("FDA"), has notified the Company that ... Drug ("IND") application before granting the Company permission to ... Dr. Chris Chapman , RCP,s President, commented, "We ... When we receive the agency,s official comments and/or recommendations, ...
(Date:7/11/2014)... 2014  Kindred Hospital Houston Northwest, with Wound ... of its new outpatient wound healing center.  The ... with chronic, hard to heal wounds. Chronic wounds ... amputation, lower leg wounds related to blood flow ... traumatic injury wounds which are complex and demonstrate ...
(Date:7/11/2014)... 11, 2014 Research and Markets ( ... "Immunoprotein Diagnostic Testing Market - Forecasts to ... of 6% and is expected to be valued ... offering. http://photos.prnewswire.com/prnh/20130307/600769 ... has been segmented according to immunoprotein types which ...
Breaking Medicine Technology:Rock Creek Pharmaceuticals Issues Update On US Investigational New Drug Application 2Kindred Hospital Houston Northwest, With Wound Care Specialists, Opens Outpatient Wound Healing And Hyperbaric Center 2Immunoprotein Diagnostic Testing Market - Forecasts to 2019: Expected to grow at the highest CAGR of 6% and is expected to be valued at USD 4,943.0 million 2
... CITY, Mo.--(BUSINESS WIRE)--Apr 11, 2007 - ... of four immunomodulatory drug,therapies combined with ... that COPAXONE(R) (glatiramer acetate,injection) was the ... sclerosis (RRMS). The study provides,the first ...
... Gloucester,Pharmaceuticals, Inc., an oncology focused biopharmaceutical,company, announced ... romidepsin will be presented at the 2007,Annual ... Research,taking place in Los Angeles, CA April ... variety of preclinical research,performed by multiple academic ...
Cached Medicine Technology:First Pharmacoeconomic Analysis with Long-Term Data Showed Copaxone,Was More Cost-Effective Than Interferon Beta Therapies for,Treatment of Relapsing-Remitting Multiple Sclerosis (RRMS) 2First Pharmacoeconomic Analysis with Long-Term Data Showed Copaxone,Was More Cost-Effective Than Interferon Beta Therapies for,Treatment of Relapsing-Remitting Multiple Sclerosis (RRMS) 3First Pharmacoeconomic Analysis with Long-Term Data Showed Copaxone,Was More Cost-Effective Than Interferon Beta Therapies for,Treatment of Relapsing-Remitting Multiple Sclerosis (RRMS) 4First Pharmacoeconomic Analysis with Long-Term Data Showed Copaxone,Was More Cost-Effective Than Interferon Beta Therapies for,Treatment of Relapsing-Remitting Multiple Sclerosis (RRMS) 5First Pharmacoeconomic Analysis with Long-Term Data Showed Copaxone,Was More Cost-Effective Than Interferon Beta Therapies for,Treatment of Relapsing-Remitting Multiple Sclerosis (RRMS) 6Gloucester Pharmaceuticals Announces Multiple Presentations of,Preclinical Romidepsin Data at American Association of Cancer,Research Annual Meeting 2Gloucester Pharmaceuticals Announces Multiple Presentations of,Preclinical Romidepsin Data at American Association of Cancer,Research Annual Meeting 3
The TV-Mag is a 1.9x focusing telescope, used mainly for watching television. It has a large objective lens giving excellent light transmission and a wide field of view....
This 6x or 8x aspheric magnifier is fitted with a distance piece and is particularly useful for patients with tremor or focusing difficulties. The magnifier can be either spectacle mounted or hand h...
The Redi-glaze spectacle magnifier is an aspheric lens, glazed into a standard Keeler LVA frame....
This set offers the full range of Keeler magnifiers and telescopes....
Medicine Products: